AI-guided CRISPR gene editing for cardiovascular disease: Current progress, transitional challenges, and future directions
Ghannam RB, Danaf N, Hamdan RCardiovascular disease (CVD) remains a leading cause of global morbidity and mortality despite major advances in pharmacological therapy, interventional cardiology, and lifestyle-based prevention. Although many current treatments reduce disease burden and improve outcomes, they often fail to address the underlying molecular and genetic mechanisms driving disease progression dot CRISPR hyphen-based
Abstract · 0 citations · DOI 10.1016/j.ahjo.2026.100999 · Retrieved 2026-11-18